21/03/2024 - 111 Inc.: 111, Inc. Fourth Quarter 2023 Earnings Presentation

DISCLAIMER

• The following presentation has been prepared by 111,. Inc. ("111" or the "Company") solely for informational purposes and should not be construed to be, directly or indirectly, in whole or in part, an offer to buy or sell and/or an invitation and/or a recommendation and/or a solicitation of an offer to buy or sell any security or instrument or to participate in any investment or trading strategy, nor shall any part of it form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities or otherwise.
• This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. Nothing contained in this document shall be relied upon as a promise or representation as to the past or future performance of the Company. Past performance does not guarantee or predict future performance.
• You acknowledge that any assessment of the Company that may be made by you will be independent of this document and that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.
• This document contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as 111's strategic and operational plans, contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control.

• Forward-lookingstatements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company's ability comply with extensive and evolving regulatory requirements, its ability to compete effectively in the evolving PRC general health and wellness market, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its pharmaceutical retail and wholesale businesses, and the Company's ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market, including its ability to cure any non-compliance with Nasdaq's continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
• This document also contains non-GAAP financial measures, the presentation of which is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the United States of America. In addition, the Company's calculation of these non-GAAP financial measures may be different from the calculation used by other companies, and therefore comparability may be limited. The reconciliation of those measures to the most comparable GAAP measures is contained within this document or the earnings press release.
• This document speaks as of December, 2023. Neither the delivery of this document nor any further discussions of the Company with any of the recipients shall, under and circumstances, create any implication that there has been no change in the affairs of the Company since that date.

Driving Operational Excellence

(Excluding Share-Based Compensation Expenses)

Selling and Marketing Expense

as % of Net Revenue

YoY -10bpsYoY -50bps

Fulfillment Expense as % of Net Revenue

YoY -40bpsYoY -30bps

Workforce

Optimization

2.7% 2.6%

3.0%

2.5%

2.9%		3.0%
	2.5%	2.7%

Streamlined

Management

Improved

2022 Q4

2023 Q4

2022

2023

Technology Expense as % of Net Revenue

YoY -30bps

0.9%

2022 Q4

2023 Q4

2022

2023

G&A Expense as % of Net Revenue

YoY -20bps

0.9%

Corporate

Governance

Technology

Investment

Fulfillment

0.6% 0.6%

0.6%

0.9%

0.9%

0.7%

Upgrade

In-House

Advisory

Department

2022 Q4

2023 Q4

2022

2023

2022 Q4	2023 Q4	2022	2023

Traditional Model

Pharmas

Primary Distributor

Secondary Distributor

Tertiary Distributor

Retail End

Consumer

Digital Model

Pharmas

111, Inc.

Fully Digitalized	Digital Marketing
Operational System
Technology Empowerment	30 + Proprietary Systems
for Pharmacies
Intelligent Supply	22 Patents
Chain

Retail End

Consumers

Data Direct Linkage & Digital Enablement

Industry Upgrade

• De-Intermediationof Industrial Supply Chain
• Transaction Automation
• Intelligent Service

Enabling

Technological

Innovation

• Industrial Informatization
• Industrial Digitalization
• Industrial AI